LONDON – Pharmaceutical company AstraZeneca reiterated its promise not to gain advantages from a COVID-19 vaccine during the pandemic, as it has said it is on track with complex treatment trials.
These promises have been driven through strong sales in their diversity of blocking solutions. Sales increased 14% to $12.6 billion in the first six months of 2020 and were backed by a solid industry in new drugs, as well as cancer and respiratory drugs.
Despite the results, CEO Pascal Soriot said he remained cautious about the uncertainty of the pandemic.
“If there’s one thing we’ve learned from this virus, it’s unpredictable,” he said. “And then we’ll have to be cautious.”
He said the source chain is on track to make 2 billion doses of vaccines at a few dollars a dose. It has also concluded 3 other distribution agreements, if the vaccine works.
“We believe there was a time in life when corporations want to mobilize and make a contribution,” he said, adding that a vaccine would be available to as many people as possible.
“This is the kind of story era in which Array … humanity is threatened as a whole,” he said.
The production charge for the vaccine, which was developed through Oxford University, is expected to be offset by government funding.
AstraZeneca has signed a series of agreements around the world to obtain the coVID-19 experimental vaccine, which was promising in the first tests. The Anglo-Swedish company has recently signed agreements with the United States, Great Britain, the European Union, the Coalition for Innovations in Epidemic Preparation, a public-private-charitable partnership founded in Norway, and Gavi, the public-private Vaccine Alliance. founding in Geneva.
It also entered into a licensing agreement with the Serum Institute of India for low- and middle-income countries and agreements with R-Pharm in Russia and SK Biopharmaceuticals Co., Ltd. in the Republic of Korea “for production and export to other countries. of the world. Markets.”
“We need to cover everybody,” Soriot said, “so everyone can have this vaccine.”